cs5931, a novel polypeptide in ciona savignyi, represses angiogenesis via inhibiting vascular endothelial growth factor (vegf) and matrix metalloproteinases (mmps)
Clicks: 299
ID: 197695
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
298 views
59 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
CS5931 is a novel polypeptide from Ciona savignyi with anticancer activities. Previous study in our laboratory has shown that CS5931 can induce cell death via mitochondrial apoptotic pathway. In the present study, we found that the polypeptide could inhibit angiogenesis both in vitro and in vivo. CS5931 inhibited the proliferation, migration and formation of capillary-like structures of HUVECs (Human Umbilical Vein Endothelial Cell) in a dose-dependent manner. Additionally, CS5931 repressed spontaneous angiogenesis of the zebrafish vessels. Further studies showed that CS5931 also blocked vascular endothelial growth factor (VEGF) production but without any effect on its mRNA expression. Moreover, CS5931 reduced the expression of matrix metalloproteinases (MMP-2 and MMP-9) both on protein and mRNA levels in HUVEC cells. We demonstrated that CS5931 possessed strong anti-angiogenic activity both in vitro and in vivo, possible via VEGF and MMPs. This study indicates that CS5931 has the potential to be developed as a novel therapeutic agent as an inhibitor of angiogenesis for the treatment of cancer.
| Reference Key |
liu2014marinecs5931,
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Ge Liu;Ming Liu;Jianteng Wei;Haijuan Huang;Yuyan Zhang;Jin Zhao;Lin Xiao;Ning Wu;Lanhong Zheng;Xiukun Lin |
| Journal | jixie gongcheng xuebao/journal of mechanical engineering |
| Year | 2014 |
| DOI |
10.3390/md12031530
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.